Financial Ratios Healwell AI Inc.
Equities
AIDX
CA42249X1006
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.070 CAD | -0.93% |
|
-10.08% | -49.29% |
| 11-07 | Healwell AI Inc., Q3 2025 Earnings Call, Nov 07, 2025 | |
| 11-06 | Healwell AI Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 | CI |
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||
Return on Assets | -15.69 | -27.24 | -24.58 | -22.14 | -23.84 | |||
Return on Total Capital | -20.34 | -38.19 | -34.91 | -30 | -30.91 | |||
Return On Equity % | -82.19 | -103.67 | -96.99 | -183.88 | -57.66 | |||
Return on Common Equity | -91.26 | -111.37 | -105.95 | -263.61 | -68.57 | |||
Margin Analysis | ||||||||
Gross Profit Margin % | 18.4 | 31.39 | 31.23 | 17.18 | 44.43 | |||
SG&A Margin | 24.87 | 69.01 | 55.29 | 191.85 | 117.28 | |||
EBITDA Margin % | -13.44 | -35.66 | -36.58 | -220.21 | -82.25 | |||
EBITA Margin % | -14.52 | -36.62 | -37.46 | -226.62 | -83.27 | |||
EBIT Margin % | -14.66 | -37.94 | -39.36 | -240.43 | -87.72 | |||
Income From Continuing Operations Margin % | -2.66 | -32.5 | -39.4 | -439.26 | -70.37 | |||
Net Income Margin % | -2.67 | -32.77 | -39.62 | -431.83 | -67.47 | |||
Net Avail. For Common Margin % | -2.67 | -32.77 | -39.62 | -439.98 | -67.33 | |||
Normalized Net Income Margin | -6.98 | -24.58 | -25.98 | -165.97 | -56.46 | |||
Levered Free Cash Flow Margin | 4.06 | -7.64 | -4.49 | -55.99 | -4.46 | |||
Unlevered Free Cash Flow Margin | 4.87 | -7.03 | -3.92 | -42.5 | -1.81 | |||
Asset Turnover | ||||||||
Asset Turnover | 1.71 | 1.15 | 1 | 0.15 | 0.43 | |||
Fixed Assets Turnover | 2.62 | 3.48 | 4.37 | 1.03 | 9.01 | |||
Receivables Turnover (Average Receivables) | 10.97 | 8.78 | 8.26 | 2.02 | 9.99 | |||
Short Term Liquidity | ||||||||
Current Ratio | 0.54 | 1.14 | 0.44 | 2.42 | 0.79 | |||
Quick Ratio | 0.46 | 0.97 | 0.38 | 2.17 | 0.69 | |||
Operating Cash Flow to Current Liabilities | 0.39 | -0.49 | -0.43 | -1.15 | -0.97 | |||
Days Sales Outstanding (Average Receivables) | 33.36 | 41.56 | 44.2 | 181.1 | 36.65 | |||
Average Days Payable Outstanding | 40.3 | 61.5 | 60.29 | 285.37 | 69.84 | |||
Long Term Solvency | ||||||||
Total Debt/Equity | 6.35K | 48.23 | 129.09 | 97.5 | 30.14 | |||
Total Debt / Total Capital | 98.45 | 32.54 | 56.35 | 49.37 | 23.16 | |||
LT Debt/Equity | 4.77K | 37.86 | 69.17 | 89.67 | 26.44 | |||
Long-Term Debt / Total Capital | 73.94 | 25.54 | 30.19 | 45.4 | 20.31 | |||
Total Liabilities / Total Assets | 98.94 | 51.15 | 70.43 | 60.03 | 41.31 | |||
EBIT / Interest Expense | -11.29 | -39.27 | -42.93 | -11.14 | -20.63 | |||
EBITDA / Interest Expense | -5.39 | -31.21 | -34.27 | -9.37 | -18.93 | |||
(EBITDA - Capex) / Interest Expense | -5.56 | -33.01 | -34.91 | -9.41 | -18.99 | |||
Total Debt / EBITDA | -5.57 | -1 | -1.04 | -1.41 | -0.71 | |||
Net Debt / EBITDA | -5.24 | -0.5 | -0.96 | -0.12 | -0.41 | |||
Total Debt / (EBITDA - Capex) | -5.4 | -0.94 | -1.02 | -1.41 | -0.71 | |||
Net Debt / (EBITDA - Capex) | -5.08 | -0.47 | -0.94 | -0.12 | -0.41 | |||
Growth Over Prior Year | ||||||||
Total Revenues, 1 Yr. Growth % | -16.67 | 23.96 | 11.3 | -29.81 | 432.62 | |||
Gross Profit, 1 Yr. Growth % | 0.21 | 16.15 | 10.72 | -66.12 | 1.28K | |||
EBITDA, 1 Yr. Growth % | 352.27 | 392.69 | 14.16 | -3.66 | 98.94 | |||
EBITA, 1 Yr. Growth % | 240.55 | 351.31 | 13.86 | -3.58 | 95.71 | |||
EBIT, 1 Yr. Growth % | 233.18 | 361.37 | 15.48 | -3.39 | 94.32 | |||
Earnings From Cont. Operations, 1 Yr. Growth % | 748.76 | 1.41K | 34.93 | 76.65 | -14.67 | |||
Net Income, 1 Yr. Growth % | 743.44 | 1.42K | 34.56 | 49.86 | -16.79 | |||
Normalized Net Income, 1 Yr. Growth % | 29.42K | 321.68 | 17.64 | 0.98 | 81.2 | |||
Diluted EPS Before Extra, 1 Yr. Growth % | 736.23 | 1.12K | 28.98 | 54.38 | -65.71 | |||
Accounts Receivable, 1 Yr. Growth % | 33.31 | 70.98 | -12.37 | -79.39 | 428.93 | |||
Net Property, Plant and Equip., 1 Yr. Growth % | -14.26 | 2.65 | -25.04 | -64.25 | 31.66 | |||
Total Assets, 1 Yr. Growth % | -1.44 | 172.34 | -25.06 | 17.68 | 133.79 | |||
Tangible Book Value, 1 Yr. Growth % | -128.29 | -1.15K | -273.47 | 27.39 | 159.51 | |||
Common Equity, 1 Yr. Growth % | -94.68 | 24.48K | -57.99 | 7.43 | 405.04 | |||
Cash From Operations, 1 Yr. Growth % | 31.4 | -268.12 | 17.58 | 29.38 | 109.47 | |||
Capital Expenditures, 1 Yr. Growth % | -30.33 | 880 | -62.55 | -77.4 | 37.88 | |||
Levered Free Cash Flow, 1 Yr. Growth % | 31.02 | -237.98 | -34.54 | 455.23 | -57.55 | |||
Unlevered Free Cash Flow, 1 Yr. Growth % | 22.81 | -213.72 | -37.99 | 784.46 | -77.38 | |||
Compound Annual Growth Rate Over Two Years | ||||||||
Total Revenues, 2 Yr. CAGR % | -7.48 | 1.63 | 17.46 | -60.88 | 93.36 | |||
Gross Profit, 2 Yr. CAGR % | 1.2 | 45.6 | 13.4 | -71.06 | 116.04 | |||
EBITDA, 2 Yr. CAGR % | 104.48 | 285.74 | 137.16 | -2.79 | 38.44 | |||
EBITA, 2 Yr. CAGR % | 80.61 | 226.27 | 126.69 | -2.69 | 37.37 | |||
EBIT, 2 Yr. CAGR % | 78.74 | 226.96 | 130.83 | -1.52 | 37.02 | |||
Earnings From Cont. Operations, 2 Yr. CAGR % | 105.96 | 1.03K | 351.87 | 43.81 | 22.77 | |||
Net Income, 2 Yr. CAGR % | 111.91 | 1.03K | 352.67 | 42 | 11.67 | |||
Normalized Net Income, 2 Yr. CAGR % | 376.58 | 3.49K | 122.73 | 1.65 | 35.27 | |||
Diluted EPS Before Extra, 2 Yr. CAGR % | - | 908.48 | 296.06 | 31.49 | -27.24 | |||
Accounts Receivable, 2 Yr. CAGR % | 7.56 | 50.98 | 22.4 | -57.5 | 4.42 | |||
Net Property, Plant and Equip., 2 Yr. CAGR % | -12.07 | -6.19 | -12.28 | -48.23 | -31.4 | |||
Total Assets, 2 Yr. CAGR % | -5.88 | 63.84 | 42.86 | -6.09 | 65.87 | |||
Tangible Book Value, 2 Yr. CAGR % | -47.75 | 72.05 | 326.01 | 48.66 | 81.82 | |||
Common Equity, 2 Yr. CAGR % | -77.55 | 261.8 | 916.31 | -32.82 | 132.93 | |||
Cash From Operations, 2 Yr. CAGR % | 7.39 | 48.63 | 40.6 | 23.34 | 64.63 | |||
Capital Expenditures, 2 Yr. CAGR % | -33.47 | 161.3 | 91.59 | -71.85 | -44.18 | |||
Levered Free Cash Flow, 2 Yr. CAGR % | - | 74.71 | -4.96 | 5.93 | 53.53 | |||
Unlevered Free Cash Flow, 2 Yr. CAGR % | - | 48.19 | -16.03 | -3.82 | 41.46 | |||
Compound Annual Growth Rate Over Three Years | ||||||||
Total Revenues, 3 Yr. CAGR % | -3.95 | 2 | 4.76 | -42.54 | -6.59 | |||
Gross Profit, 3 Yr. CAGR % | 0.7 | 29.39 | 32.9 | -54.01 | 4.87 | |||
EBITDA, 3 Yr. CAGR % | 68.52 | 139.61 | 157.06 | 66.98 | 23.42 | |||
EBITA, 3 Yr. CAGR % | 54.91 | 116.85 | 129.71 | 62.28 | 22.83 | |||
EBIT, 3 Yr. CAGR % | 54.49 | 117.23 | 131.12 | 64.78 | 23.52 | |||
Earnings From Cont. Operations, 3 Yr. CAGR % | 437.27 | 300.4 | 457.53 | 215.13 | 20.84 | |||
Net Income, 3 Yr. CAGR % | 612.57 | 308.94 | 457.02 | 213.14 | 18.83 | |||
Normalized Net Income, 3 Yr. CAGR % | 946.34 | 362.77 | 1.05K | 63.33 | 23.25 | |||
Diluted EPS Before Extra, 3 Yr. CAGR % | - | - | 408.1 | 176.02 | -15.99 | |||
Accounts Receivable, 3 Yr. CAGR % | - | 25.53 | 25.94 | -32.4 | -1.51 | |||
Net Property, Plant and Equip., 3 Yr. CAGR % | - | -7.42 | -12.95 | -34.97 | -29.34 | |||
Total Assets, 3 Yr. CAGR % | - | 34.12 | 26.23 | 33.92 | 27.27 | |||
Tangible Book Value, 3 Yr. CAGR % | - | 41.88 | 72.52 | 184.88 | 79 | |||
Common Equity, 3 Yr. CAGR % | - | 131.41 | 76.51 | 380.54 | 31.61 | |||
Cash From Operations, 3 Yr. CAGR % | 6.36 | 24.69 | 37.46 | 36.75 | 47.16 | |||
Capital Expenditures, 3 Yr. CAGR % | -39.38 | 63.09 | 36.75 | -8.09 | -52.2 | |||
Levered Free Cash Flow, 3 Yr. CAGR % | - | - | 25.95 | 15.69 | -21.9 | |||
Unlevered Free Cash Flow, 3 Yr. CAGR % | - | - | 10.84 | 1.7 | -40.63 | |||
Compound Annual Growth Rate Over Five Years | ||||||||
Total Revenues, 5 Yr. CAGR % | - | - | 4.1 | -30.48 | -3.38 | |||
Gross Profit, 5 Yr. CAGR % | - | - | 19.05 | -28.92 | 19.58 | |||
EBITDA, 5 Yr. CAGR % | - | - | 78.21 | 67.02 | 94.69 | |||
EBITA, 5 Yr. CAGR % | - | - | 67.61 | 57.38 | 81.56 | |||
EBIT, 5 Yr. CAGR % | - | - | 68.7 | 58.3 | 82.32 | |||
Earnings From Cont. Operations, 5 Yr. CAGR % | - | - | 401.33 | 165.83 | 195.85 | |||
Net Income, 5 Yr. CAGR % | - | - | 494.3 | 167.86 | 192.88 | |||
Normalized Net Income, 5 Yr. CAGR % | - | - | 467.4 | 152.39 | 374.74 | |||
Diluted EPS Before Extra, 5 Yr. CAGR % | - | - | - | - | 127.02 | |||
Accounts Receivable, 5 Yr. CAGR % | - | - | - | -18.6 | 16.84 | |||
Net Property, Plant and Equip., 5 Yr. CAGR % | - | - | - | -26.63 | -20.86 | |||
Total Assets, 5 Yr. CAGR % | - | - | - | 16.3 | 40.8 | |||
Tangible Book Value, 5 Yr. CAGR % | - | - | - | 44.55 | 76.18 | |||
Common Equity, 5 Yr. CAGR % | - | - | - | 41.1 | 97.22 | |||
Cash From Operations, 5 Yr. CAGR % | - | - | 18.92 | 24.15 | 47.74 | |||
Capital Expenditures, 5 Yr. CAGR % | - | - | -3.95 | -19.23 | -5.69 | |||
Levered Free Cash Flow, 5 Yr. CAGR % | - | - | - | - | 7.78 | |||
Unlevered Free Cash Flow, 5 Yr. CAGR % | - | - | - | - | -14.4 |
- Stock Market
- Equities
- AIDX Stock
- Financials Healwell AI Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















